Neurocrine Biosciences, Inc. NBIX

NAS: NBIX | ISIN: US64125C1099   3/07/2025
129,11 USD (-0,22%)
(-0,22%)   3/07/2025

15 mei 2025 · Neurocrine Biosciences Presents Data on Improvements in Physiologic Glucocorticoid Dosing and Select Reproductive Hormones in Patients with Classic Congenital Adrenal Hyperplasia Taking CRENESSITY™ (crinecerfont) · Persbericht

14 mei 2025 · Neurocrine Biosciences Presents Findings Contributing to the Growing Body of Evidence on the Impact of High-Dose Glucocorticoids on Clinical Outcomes in Congenital Adrenal Hyperplasia · Persbericht

8 mei 2025 · Neurocrine Biosciences Announces New Results from Exploratory Analyses of the Phase 3 CAHtalyst™ Pediatric Study Demonstrating CRENESSITY™ Reduces Glucocorticoid Dosing While Maintaining or Improving Androstenedione Across Patient Subgroups · Persbericht

6 mei 2025 · Neurocrine Biosciences to Present at Upcoming Investor Conferences in May · Persbericht

6 mei 2025 · Neurocrine Biosciences and Carnie Wilson Team Up to Launch ConnectING with Carnie™ Awareness Campaign for People with Tardive Dyskinesia · Persbericht

5 mei 2025 · Neurocrine Biosciences Reports First Quarter 2025 Financial Results and Reaffirms 2025 Financial Guidance · Persbericht

5 mei 2025 · Neurocrine Biosciences Announces New Survey Revealing Need for Routine Screening and Earlier Diagnosis for People Living with Tardive Dyskinesia · Persbericht

30 april 2025 · Neurocrine Biosciences Initiates Phase 3 Registrational Program for NBI-1117568 as Potential Treatment for Adults with Schizophrenia · Persbericht

24 april 2025 · Neurocrine Biosciences Publishes Analysis Showing Long-Term Efficacy and a Consistent Safety Profile of INGREZZA® (valbenazine) Capsules in Older Adults with Tardive Dyskinesia in The Journal of Clinical Psychiatry · Persbericht

14 april 2025 · Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2025 Financial Results · Persbericht

4 april 2025 · Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer · Persbericht

31 maart 2025 · Neurocrine Biosciences Presents Real-World Data on Therapeutic Dose Attainment and Dosing Trends of VMAT2 Inhibitors in Patients With Tardive Dyskinesia · Persbericht

20 maart 2025 · Neurocrine Biosciences Presents 48-Week Remission Data on Treatment of Tardive Dyskinesia With INGREZZA® (valbenazine) Capsules · Persbericht

17 maart 2025 · Neurocrine Biosciences Presents New KINECT®-HD Data Showing Significant Reduction in Chorea Across Body Regions With INGREZZA® (valbenazine) Capsules · Persbericht

11 maart 2025 · Neurocrine Biosciences to Present at the Stifel 2025 Virtual CNS Forum · Persbericht

5 maart 2025 · Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBI-1140675, a Second-Generation VMAT2 Inhibitor, in Healthy Adults · Persbericht

12 september 2024 · Neurocrine Biosciences Provides Update on ERUDITE™ Phase 2 Data for Luvadaxistat in Adults with Cognitive Impairment Associated with Schizophrenia · Persbericht

10 september 2024 · Neurocrine Biosciences to Participate at the 2024 Cantor Global Healthcare Conference · Persbericht

28 augustus 2024 · Neurocrine Biosciences to Participate at Investor Conferences in September · Persbericht

28 augustus 2024 · Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1117568 in Adults with Schizophrenia · Persbericht

Mijn selecties